

Not for release to US wire services or distribution in the United States

Cleansing Notice under section 708AA(2)(f) and 708A(5)(e) of the Corporations Act 2001 (Cth)

This notice is given by Microba Life Sciences Limited ('Company' or 'Microba') under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) as modified by *ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84* (**Corporations Act**).

On 19 October 2023, Microba announced the launch of a A\$20.0 million pro rata accelerated non-renounceable entitlement offer (**Entitlement Offer**) of new fully paid ordinary shares (**Entitlement Offer Shares**) at an offer price of A\$0.23 per Entitlement Offer Share (**Offer Price**).

The Entitlement Offer is comprised of an offer of 1 Entitlement Offer Share for every 4 shares held as at 7.00pm (Sydney time) on Monday, 23 October 2023 by shareholders in Australia, New Zealand and certain other jurisdictions (see further details in the ASX Announcement lodged on 19 October 2023), to raise gross proceeds of up to A\$20.0 million.

A retail offer booklet will be dispatched to eligible retail shareholders (**Eligible Retail Shareholders**) on Thursday, 26 October 2023.

Cleansing Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) – Entitlement Offer

The Company confirms the following:

1. the Company will offer the Entitlement Offer Shares for issue without disclosure to investors under Part 6D.2 of the Corporations Act;
2. this notice is being given under section 708AA(2)(f) of the Corporations Act;
3. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) sections 674 and 674A of the Corporations Act;
4. as at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Corporations Act. To that end, please see the excluded information notice lodged immediately prior to this notice.
5. the potential effect that the Entitlement Offer will have on the control of the Company, and the consequences of that effect, will depend on a number of factors including the number of Entitlement Offer Shares taken up by each eligible shareholder. However, the Company notes the following:

Structure of the Entitlement Offer

- (a) The number of Entitlement Offer Shares which will be issued under the Entitlement Offer is approximately 87 million Entitlement Offer Shares (subject to rounding of fractional entitlements) to raise up to A\$20.0 million, equating to approximately 20% of all the issued shares in the Company following completion of the Entitlement Offer.
- (b) The Entitlement Offer will be conducted in two parts, an institutional component (**Institutional Entitlement Offer**) and a retail component (**Retail Entitlement Offer**).
- (c) The Company will offer a shortfall oversubscription facility as part of the Retail Entitlement Offer (**Oversubscription Facility**). The key terms of the Oversubscription Facility will be as follows:

- A. Under the Oversubscription Facility, Eligible Retail Shareholders who take up their entitlement in full (but excluding those persons in respect of the Company who are described in Listing Rule 10.11.1 to 10.11.5) will be able to apply for additional Entitlement Offer Shares in the Company in excess of their entitlement (**Shortfall Application**), which represents the lower of that number which represents 100% of their Entitlement or A\$50,000 worth of Entitlement Offer Shares (**Additional New Share Cap**) subject to the Corporations Act, the ASX Listing Rules and all other applicable laws and regulations; and
- B. to the extent Shortfall Applications exceed the number of Entitlement Offer Shares available under the facility, the Company will scale back applications:
- (I) having regard to all relevant circumstances, including the Eligible Retail Shareholder's underlying shareholding at the Record Date and in the event that an application for additional New Shares is received from an Eligible Retail Shareholder which is in excess of the Additional New Share Cap; and
 - (II) to ensure compliance with the ASX Listing Rules, the Corporations Act and all other applicable laws.

Impact of the Entitlement Offer on Control of the Company

- (d) Based on the substantial holding notices that have been given to Microba and lodged with the ASX on or before the date of this notice, the current substantial shareholders of Microba as at the date of this notice are:

Substantial Shareholder	Number of existing Shares	Voting Power (%)
Sonic Healthcare Limited (through A.C.N. 002 889 545 Pty Ltd)	68,589,498	19.93%
Perennial Value Management Limited	40,232,627	11.69%
SA Microba Holdings Pty Ltd	31,524,277	9.16%
Thorney Technologies Limited/Tiga Trading Pty Ltd	24,660,153	7.17%
Macrogen, Inc.	17,828,431	5.18%

- (e) If all Eligible Shareholders take-up their full entitlement under the Entitlement Offer, they will maintain their existing percentage interest in the total issued share capital of Microba. In these circumstances, the Entitlement Offer will have no significant effect on control of the Company.
- (f) If an Eligible Shareholder takes-up their full entitlement under the Entitlement Offer, but the Entitlement Offer is not otherwise fully subscribed, the holding of that Eligible Shareholder may increase.
- (g) A.C.N. 002 889 545 Pty Ltd (**Sonic**) has indicated it will take-up its full entitlement. This could result in it increasing to a maximum of 22.416% on completion of the Institutional Entitlement Offer, but would reduce on completion of the Retail Entitlement Offer subject to the amount subscribed under the Retail Entitlement Offer. For this increase, Sonic intends to rely on the exception to section 606 of the Corporations Act set out in item 9 of section 611 of the Corporations Act, being the 'creep exception'.
- (h) If any Eligible Shareholders take-up their full entitlement and participate in the Oversubscription Facility, they may increase their holding in Microba, but always subject to item (k) as detailed below.
- (i) To the extent that an Eligible Shareholder does not take-up their entitlements under the Entitlement Offer, that Eligible Shareholder's percentage holding in Microba will be diluted by the issue of the Entitlement Offer Shares under the Entitlement Offer. The extent of the dilution will depend on which Eligible Shareholders take up their Entitlement.
- (j) The proportional interests of Microba Shareholders who are not Eligible Shareholders will be diluted because such Shareholders are not entitled to participate in the Entitlement Offer.

- (k) So far as Microba is aware, with the exception as detailed in paragraph (g) above, no shareholder will, as a result of the Entitlement Offer, increase its voting power from below 20% to above 20% interest and the issue of the Entitlement Offer Shares is not expected to have a material effect or consequence of control on Microba.
- (l) In the event there is a shortfall under the Entitlement Offer (including under the Oversubscription Facility), those shortfall shares may be placed by the Company at the discretion of the Company within three months after the Entitlement Offer closes and at a price no less than the price at which the Entitlement Offer Shares were offered under the Entitlement Offer.

Cleansing Notice - Share issue

In respect of the ordinary shares issued on 19 October 2023 on the exercise of employee options (**Shares**), the Company gives notice as required under section 708A(5)(e) of the Corporations Act as follows:

- 1 the Company issued the Shares on exercise of the options without disclosure to eligible shareholders under Part 6D.2 of the Corporations Act;
- 2 this notice is being given to the ASX by the Company under section 708A(5)(e) of the Corporations Act;
- 3 as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of and section 674A the Corporations Act; and
- 4 as at the date of this notice, there is no "excluded information" as defined in section 708A(7) or section 708A(8) of the Corporations Act that has not already been disclosed to investors generally. To that end, please see the excluded information notice lodged immediately prior to this notice.

This announcement has been authorised for release by the Board.

For further information, please contact:

Dr Luke Reid

Chief Executive Officer

E: Luke.Reid@microba.com

Investor / Media Relations

E: investor@microba.com

W: <https://ir.microba.com/>

[Join our Investor Mailing List](#)

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

Disclaimer

Forward looking statements

This document contains certain "forward-looking statements". The words "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this document are based on assumptions and contingencies that are subject to change without notice and involve known and unknown risks and uncertainties and other factors that are beyond the control of Microba, its directors and management. This includes

statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. These statements may assume the success of Microba's business strategies. The success of any of those strategies will be realised in the period for which the forward-looking statement may have been prepared or otherwise. Readers are cautioned not to place undue reliance on forward-looking statements and except as required by law or regulation, none of Microba, its representatives or advisers assumes any obligation to update these forward-looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this document. The forward-looking statements are based on information available to Microba as at the date of this document. Except as required by law or regulation (including the ASX Listing Rules), none of Microba, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

Not an offer in the United States

This document has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This document does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or in any other jurisdiction in which such an offer would be illegal. Any securities described in this document have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or the securities laws of any state or jurisdiction of the United States. Accordingly, the securities described in this document may not be offered or sold, directly or indirectly, in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the US Securities Act and applicable securities laws of any state or other jurisdiction of the United States

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.